92 related articles for article (PubMed ID: 29217295)
1. Investigation of a minor groove-binding polyamide targeted to E2F1 transcription factor in chronic myeloid leukaemia (CML) cells.
Hayatigolkhatmi K; Padroni G; Su W; Fang L; Gómez-Castañeda E; Hsieh YC; Jackson L; Holyoake TL; Pellicano F; Burley GA; Jørgensen HG
Blood Cells Mol Dis; 2018 Mar; 69():119-122. PubMed ID: 29217295
[No Abstract] [Full Text] [Related]
2. An investigation of targeted inhibition of transcription factor activity with pyrrole imidazole polyamide (PA) in chronic myeloid leukemia (CML) blast crisis cells.
Hayatigolkhatmi K; Padroni G; Su W; Fang L; Gómez-Castañeda E; Hsieh YC; Jackson L; Pellicano F; Burley GA; Jørgensen HG
Bioorg Med Chem Lett; 2019 Sep; 29(18):2622-2625. PubMed ID: 31378570
[TBL] [Abstract][Full Text] [Related]
3. Experimental and integrative analyses identify an ETS1 network downstream of BCR-ABL in chronic myeloid leukemia (CML).
Desterke C; Voldoire M; Bonnet ML; Sorel N; Pagliaro S; Rahban H; Bennaceur-Griscelli A; Cayssials E; Chomel JC; Turhan AG
Exp Hematol; 2018 Aug; 64():71-83.e8. PubMed ID: 29733872
[TBL] [Abstract][Full Text] [Related]
4. BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia.
Roy S; Jørgensen HG; Roy P; Abed El Baky M; Melo JV; Strathdee G; Holyoake TL; Bartholomew C
Br J Haematol; 2012 May; 157(4):446-56. PubMed ID: 22372463
[TBL] [Abstract][Full Text] [Related]
5. Identification of target genes using gene expression profile of granulocytes from patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
Mascarenhas Cdo C; Ferreira da Cunha A; Brugnerotto AF; Gambero S; de Almeida MH; Carazzolle MF; Pagnano KB; Traina F; Costa FF; de Souza CA
Leuk Lymphoma; 2014 Aug; 55(8):1861-9. PubMed ID: 24144310
[TBL] [Abstract][Full Text] [Related]
6. Liposomal bortezomib is active against chronic myeloid leukemia by disrupting the Sp1-BCR/ABL axis.
Yang X; Pang J; Shen N; Yan F; Wu LC; Al-Kali A; Litzow MR; Peng Y; Lee RJ; Liu S
Oncotarget; 2016 Jun; 7(24):36382-36394. PubMed ID: 27144331
[TBL] [Abstract][Full Text] [Related]
7.
Pellicano F; Park L; Hopcroft LEM; Shah MM; Jackson L; Scott MT; Clarke CJ; Sinclair A; Abraham SA; Hair A; Helgason GV; Aspinall-O'Dea M; Bhatia R; Leone G; Kranc KR; Whetton AD; Holyoake TL
Blood; 2018 Apr; 131(14):1532-1544. PubMed ID: 29437554
[TBL] [Abstract][Full Text] [Related]
8. Functional Profiling Identifies Determinants of Arsenic Trioxide Cellular Toxicity.
Sobh A; Loguinov A; Yazici GN; Zeidan RS; Tagmount A; Hejazi NS; Hubbard AE; Zhang L; Vulpe CD
Toxicol Sci; 2019 May; 169(1):108-121. PubMed ID: 30815697
[TBL] [Abstract][Full Text] [Related]
9. PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
Gupta P; Kathawala RJ; Wei L; Wang F; Wang X; Druker BJ; Fu LW; Chen ZS
Cancer Lett; 2016 Dec; 383(2):220-229. PubMed ID: 27720778
[TBL] [Abstract][Full Text] [Related]
10. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
11. MPT0B169, a New Antitubulin Agent, Inhibits Bcr-Abl Expression and Induces Mitochondrion-Mediated Apoptosis in Nonresistant and Imatinib-Resistant Chronic Myeloid Leukemia Cells.
Wong SM; Liu FH; Lee YL; Huang HM
PLoS One; 2016; 11(1):e0148093. PubMed ID: 26815740
[TBL] [Abstract][Full Text] [Related]
12. A report of early cytogenetic response to imatinib in two patients with chronic myeloid leukemia at accelerated phase and carrying the e19a2 BCR-ABL transcript.
Li X; Yang J; Chen X; Liu J; Li H; Zheng J; He Y; Chen Z; Huang S
Cancer Genet Cytogenet; 2007 Jul; 176(2):166-8. PubMed ID: 17656262
[TBL] [Abstract][Full Text] [Related]
13. EPS8 regulates proliferation, apoptosis and chemosensitivity in BCR-ABL positive cells via the BCR-ABL/PI3K/AKT/mTOR pathway.
Huang R; Liu H; Chen Y; He Y; Kang Q; Tu S; He Y; Zhou X; Wang L; Yang J; Wu A; Li Y
Oncol Rep; 2018 Jan; 39(1):119-128. PubMed ID: 29192326
[TBL] [Abstract][Full Text] [Related]
14. Novel approach for coexpression analysis of E2F1-3 and MYC target genes in chronic myelogenous leukemia.
Wang F; Chan LW; Cho WC; Tang P; Yu J; Shyu CR; Tsui NB; Wong SC; Siu PM; Yip SP; Yung BY
Biomed Res Int; 2014; 2014():439840. PubMed ID: 25180182
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of γ-catenin inhibits CML cell growth and potentiates the response of CML cells to imatinib through β-catenin inhibition.
Niu CC; Zhao C; Yang ZD; Zhang XL; Wu WR; Pan J; Zhao C; Li ZQ; Ding W; Yang Z; Si WK
Int J Mol Med; 2013 Feb; 31(2):453-8. PubMed ID: 23233089
[TBL] [Abstract][Full Text] [Related]
16. A derivative of epigallocatechin-3-gallate induces apoptosis via SHP-1-mediated suppression of BCR-ABL and STAT3 signalling in chronic myelogenous leukaemia.
Jung JH; Yun M; Choo EJ; Kim SH; Jeong MS; Jung DB; Lee H; Kim EO; Kato N; Kim B; Srivastava SK; Kaihatsu K; Kim SH
Br J Pharmacol; 2015 Jul; 172(14):3565-78. PubMed ID: 25825203
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: A review.
Yang K; Fu LW
Crit Rev Oncol Hematol; 2015 Mar; 93(3):277-92. PubMed ID: 25500000
[TBL] [Abstract][Full Text] [Related]
18. Imatinib mesylate resistance in a chronic myeloid leukemia patient with a novel e8a2 BCR-ABL transcript variant.
Qin YZ; Jiang B; Jiang Q; Zhang Y; Jiang H; Li JL; Zhu HH; Li LD; Liu YR; Chen SS; Huang XJ
Acta Haematol; 2008; 120(3):146-9. PubMed ID: 19039205
[TBL] [Abstract][Full Text] [Related]
19. Differences in BCL-X(L) expression and STAT5 phosphorylation in chronic myeloid leukaemia patients.
Gutiérrez-Castellanos S; Cruz M; Rabelo L; Godínez R; Reyes-Maldonado E; Riebeling-Navarro C
Eur J Haematol; 2004 Apr; 72(4):231-8. PubMed ID: 15089759
[TBL] [Abstract][Full Text] [Related]
20. Platinum pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via DUB inhibition-dependent caspase activation and Bcr-Abl downregulation.
Lan X; Zhao C; Chen X; Zhang P; Zang D; Wu J; Chen J; Long H; Yang L; Huang H; Wang X; Shi X; Liu J
Cell Death Dis; 2017 Jul; 8(7):e2913. PubMed ID: 28682311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
